Opinion | To save Canada, Mark Carney is courting foreign money. He’s risking an ‘investment invasion’ - Toronto Star

Canada’s largest trade mission to India in 30 years has netted about 30 commercial partnerships worth $300 million, according to International Trade Minister Maninder Sidhu. "It’s a market we can’t ignore," Sidhu told CBC News in an interview in Mumbai this week. A weeklong trade pitch to India wrapped up Friday in Bengaluru, a southern Indian city with a large high-tech industry. The 300-member Team Canada also visited Mumbai to connect Canadian businesses and industry with Indian ventures. At a news conference, Sidhu announced a partnership between the international airports in Vancouver and Bengaluru, "laying the groundwork for direct air service between Canada and one of the world's fastest-growing markets," he said. The trade minister also highlighted that Canada’s Fairfax Financial Holdings acquired a majority stake in IDBI, an Indian bank, for close to $8 billion, the largest-ever foreign investment by a Canadian entity in India’s financial sector, according to Sidhu. "It shows the enormous opportunity for Canadian investors doing business here in India. And it's a vote of confidence in the Canada-India relationship," he said.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.